Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
90 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014', provides an overview of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Recurrent Head And Neck Cancer Squamous Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Recurrent Head And Neck Cancer Squamous Cell Carcinoma Overview 7 Therapeutics Development 8 Pipeline Products for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Overview 8 Pipeline Products for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis 9 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies 10 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies 15 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development 16 Amgen Inc. 16 Genentech, Inc. 17 MedImmune, LLC 18 Novartis AG 19 Ono Pharmaceutical Co., Ltd. 20 Pfizer Inc. 21 Merck KGaA 22 Oncolytics Biotech Inc. 23 Panacea Biotec Limited 24 PCI Biotech AS 25 Glycotope GmbH 26 VentiRx Pharmaceuticals, Inc. 27 Immunovative Therapies, Ltd. 28 AlphaMab Co., Ltd 29 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Target 31 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 pelareorep - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 nivolumab - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 dacomitinib - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 bleomycin sulfate - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 cetuximab biobetter - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 futuximab - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 motolimod - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 duligotuzumab - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 durvalumab - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 AlloVax - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 BYL-719 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 cetuximab biosimilar - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 cetuximab biosimilar - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 cetuximab biosimilar - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Recent Pipeline Updates 67 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects 86 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products 87 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones 88 Featured News & Press Releases 88 May 15, 2013: Boehringer Ingelheim To Present Five Abstracts For Afatinib At ASCO 2013 88 Appendix 89 Methodology 89 Coverage 89 Secondary Research 89 Primary Research 89 Expert Panel Validation 89 Contact Us 90 Disclaimer 90
List of Tables Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, H2 2014 8 Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Comparative Analysis by Late Stage Development, H2 2014 12 Comparative Analysis by Clinical Stage Development, H2 2014 13 Comparative Analysis by Early Stage Development, H2 2014 14 Products under Development by Companies, H2 2014 15 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc., H2 2014 16 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genentech, Inc., H2 2014 17 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MedImmune, LLC, H2 2014 18 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG, H2 2014 19 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 20 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Pfizer Inc., H2 2014 21 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck KGaA, H2 2014 22 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H2 2014 23 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2014 24 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by PCI Biotech AS, H2 2014 25 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Glycotope GmbH, H2 2014 26 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2014 27 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunovative Therapies, Ltd., H2 2014 28 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AlphaMab Co., Ltd, H2 2014 29 Assessment by Monotherapy Products, H2 2014 30 Number of Products by Stage and Target, H2 2014 32 Number of Products by Stage and Mechanism of Action, H2 2014 34 Number of Products by Stage and Route of Administration, H2 2014 36 Number of Products by Stage and Molecule Type, H2 2014 38 Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H2 2014 67 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects, H2 2014 86 Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products, H2 2014 87
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.